Floatz logo

Therapeutic Asset Ratings

13,155 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pembrolizumab
Clear Cell Renal Carcinoma
Sairopa B.V.P2B (60)
Pembrolizumab
Mismatch Repair Cancer Syndrome
ImmunoVaccine Technologies, Inc. (IMV Inc.)P2B (60)
Pembrolizumab
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)P2B (60)
Pembrolizumab
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2B (60)
Pembrolizumab
Fallopian Tube Endometrioid Adenocarcinoma
Roswell Park Cancer InstituteP2B (60)
Pembrolizumab
Female Reproductive System Neoplasm
Sheba Medical CenterP2B (60)
Pembrolizumab
Gliosarcoma
Mayo ClinicP2B (60)
Pembrolizumab
Urethra Cancer
Emory UniversityP2B (60)
Pembrolizumab
Prostate Small Cell Carcinoma
Rahul AggarwalP2B (60)
Pembrolizumab
Renal Pelvis/Ureter Urothelial Carcinoma
Dana-Farber Cancer InstituteP2B (60)
Pembrolizumab
Epithelial Neoplasm
Sheba Medical CenterP2B (60)
Pembrolizumab
Neuroendocrine Carcinoma
Ochsner Health SystemP2B (60)
Pembrolizumab
Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
Northwestern UniversityP2B (60)
Pembrolizumab
Ocular Melanoma
H. Lee Moffitt Cancer Center and Research InstituteP2B (60)
Pembrolizumab
Oropharyngeal Carcinoma
Inhibrx Biosciences, IncP2B (60)
Pembrolizumab
Ovarian Disorder
Sheba Medical CenterP2B (60)
Pembrolizumab
Ovarian Carcinosarcoma
Mayo ClinicP2B (60)
Pembrolizumab
Malignant Pleural Mesothelioma
NuCana plcP2B (60)
Pembrolizumab
Rectal Cancer
Essen BiotechP2B (60)
Pembrolizumab
Angioimmunoblastic T-Cell Lymphoma
AstraZenecaP2B (60)
Pembrolizumab
Enteropathy-Associated T-Cell Lymphoma
Northwestern UniversityP2B (60)
Pembrolizumab
Hepatosplenic T-Cell Lymphoma
Northwestern UniversityP2B (60)
Pembrolizumab
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Northwestern UniversityP2B (60)
Pembrolizumab
Refractory Malignant Neoplasm
GV20 TherapeuticsP2B (60)
Pembrolizumab
Salivary Gland Cancer
OncoC4, Inc.P2B (60)
Showing 2076 to 2100 of 13,155 assets
PreviousPage 84 of 527Next